ScreenPoint Medical, a Nijmegen-based company developing artificial intelligence tools for breast cancer detection and risk assessment, has raised $16 million in new funding.
The round includes $14 million from existing investors Insight Partners and Siemens Healthineers, alongside $2 million in non-dilutive research grants. The company did not disclose the round type.
ScreenPoint Medical said the capital will be used for product innovation, international expansion, and other strategic initiatives. Its Transpara breast AI platform is currently deployed in more than 30 countries, reflecting growing adoption of AI tools in breast imaging and screening workflows.
The investment adds to continued backing from existing investors as healthcare providers increasingly look to AI to improve cancer detection, risk assessment, and radiology efficiency.
The round includes $14 million from existing investors Insight Partners and Siemens Healthineers, alongside $2 million in non-dilutive research grants. The company did not disclose the round type.
ScreenPoint Medical said the capital will be used for product innovation, international expansion, and other strategic initiatives. Its Transpara breast AI platform is currently deployed in more than 30 countries, reflecting growing adoption of AI tools in breast imaging and screening workflows.
The investment adds to continued backing from existing investors as healthcare providers increasingly look to AI to improve cancer detection, risk assessment, and radiology efficiency.